An End-of-study Subgroup Analysis of Black Patients From the Phase 2 GRIFFIN (AFT-29) Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients With Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM)
   Google Scholar   
Citation:
Blood vol 140 (suppl 1) 10154–6
Meeting Instance:
ASH 2022
Year:
2022
Type:
Abstract
Sub type:
Poster Discussion
Funding:
AFT
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
3685  
Program:
OGC
Primary Committee:
Myeloma
Sec. Committees:
   
Pharmas:
Janssen  
Grants:
 
Corr. Author:
 
Authors:
                                         
Networks:
KANSAS, LAPS-IL036, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-NY016, LAPS-OH007, LAPS-TX011, MD015, NC002, NE003, OH008   
Study
AFT-29 (GRIFFIN)
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: